BNR.US Burning Rock Biotech Ltd

Healthcare Biotechnology USA Stocks
15.90 USD
Close of Nov 14, 2026
6.79 41.72
Market cap
USD 140M
P/E
-
P/B
1.85x
ROE
-14.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is BNR.US undervalued?

Graham number

The Graham number of Burning Rock Biotech Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Burning Rock Biotech Ltd fundamental analysis

No fundamental analysis for Burning Rock Biotech Ltd yet.

Burning Rock Biotech Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Burning Rock Biotech Ltd

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, pros…

Full company profile